reiter buy lead life scienc platform
attend annual investor day nyc mark anniversari
present highlight evolut platform market portfolio team
posit compani growth ahead creat pre-emin life
scienc real estat platform serv research commun hub market
mani origin cluster submarket almost fulli built next growth
opportun creat mega cluster expand submarket footprint
current market reiter buy rate bump po
guidanc st ss noi better expect
introduc guidanc midpoint
street forecast same-stor noi growth cash vs estim
flat occup cash leas spread
rent bump averag typic gener growth leas
spread didnt provid invest gain guidanc point histor
ffo averag guid shave estim fewer gain
plan fund develop spend acquisit
cash flow increment debt debt capit proce held
cash combin asset sale partial interest sale
common equiti target net debt ebitda offic peer
market still tight watch elect regulatori risk
fundament market remain tight healthi pipelin tenant
demand see insid key question mind head impact
elect regulatori uncertainti life scienc invest tenant
decis make earli know watch tenant leas volum
close posit current era histor research breakthrough effici
fda approv process larg sum public privat fund also watch
progress asset sale capit rais activ fund develop
net dbt
investor day outlin next phase
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
normal fund oper ffo
fund oper ffo
properti
return invest capit
own develop offic laboratori
space leas mainli biotechnolog
pharmaceut scientif research institut
relat govern agenc tenant also
grown exposur technolog tenant
portfolio target market compani
portfolio focus center life scienc
research us boston san francisco new
york san diego seattl washington dc
research triangl nc
uniqu oper platform focus
acquisit develop redevelop
leas lab biotech real estat life
scienc industri view healthcar life-
scienc tech focus tenant base
prove resili drive outsiz growth
base buy rate factor plu valuat
current life scienc vacanc rate east cambridg san francisco
nyc san diego seattl maryland
research triangl greater boston leas expir total sf versu
sf market tenant demand san francisco expir total sf vs sf
demand san diego total sf vs sf demand seattl total sf vs
sf demand
rais po
follow investor day review model increas
price object price object repres
premium unchang forward estim deriv estim
appli unchang cap rate forward noi estim
price object premium reflect strength
platform life scienc real estat sector off-set regulatori uncertainti
appli cap rate forward noi estim calcul
use cap rate base view interest rate next year
compar transact comp market exposur
upsid risk po capit rais oper condit develop yield
expect downsid risk oper condit yield
expect also expos risk biotech sector privat
public fund regulatori chang fda approv process prolong
period tight credit market condit could weigh access capit borrow
cost direct real estat valu
jame feldman herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
apart invest manag co
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
